Diginex Founder Pours $25.4 Million Into Own Stock as Short Interest Spikes Ahead of June 12 Deal Deadline
04.06.2026 - 15:53:38 | boerse-global.de
Miles Pelham, Diginex’s chairman and founder, has staked $25.4 million of his own capital in the company since its IPO, at an average price of $5.69 per share. That personal commitment comes as short sellers have cranked up their bets against the stock, with short interest surging roughly 120% to nearly 750,000 shares, or 4.49% of the float. The timing underscores the tension between a founder’s conviction and market skepticism as a make-or-break acquisition deadline approaches.
The British RegTech firm has not been idle on the product front. It recently unveiled “Risk-to-Remedy,” a full-cycle supply chain due diligence platform that stitches together existing modules — LUMEN for risk assessment and APPRISE for workforce engagement — with structured grievance and remediation tools. The solution is built on the January 2026 acquisition of The Remedy Project and targets companies grappling with Germany’s supply chain due diligence law and the EU’s CSDDD directive. By combining blockchain, AI, and data analytics, Diginex aims to support reporting frameworks such as GRI, SASB, and TCFD. Yet the product news has done little to deter bearish sentiment.
The real inflection point is the planned acquisition of AI platform Resulticks, now set to close by June 12, 2026 after one extension from the original May 29 deadline. Diginex has broadened its narrative around the deal, positioning it not merely as an ESG and compliance play but as a convergence of sustainability data, real-time customer intelligence, and decisioning capabilities. The financial targets attached to Resulticks are eye-catching: approximately $150 million in annual revenue and up to $50 million in EBITDA. However, the company has explicitly cautioned that these figures are contingent on the transaction closing — they are not consolidated results. An SEC filing notes that outstanding closing conditions still have to be met, and no guarantee exists that the deal will go through.
Should investors sell immediately? Or is it worth buying Diginex?
Market skepticism is understandable given Diginex’s standalone numbers. For the fiscal year ended March 2025, revenue climbed 57% to $2.04 million, but the net loss stood at $5.21 million. The market capitalization hovers around $34 million, with shares trading between $1.14 and $1.26 — a far cry from Pelham’s average purchase price. Liquidity is healthy: the company holds more cash than short-term liabilities, with a current ratio of 3.56. But that balance sheet strength alone hasn’t convinced bears, who have piled on as the Resulticks deal clock ticks.
Pelham’s $25.4 million personal investment may help shift the narrative. Diginex points to it as evidence of long-term belief in the strategy, but for the moment, it’s a signal that has failed to close the gap between the founder’s $5.69 average entry and the stock’s current sub-$1.30 range. Whether that gap narrows depends entirely on whether the Resulticks acquisition crosses the finish line on June 12. A successful close would remove the biggest overhang on the stock; a failure would validate the short sellers’ thesis.
Ad
Diginex Stock: New Analysis - 4 June
Fresh Diginex information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
